Scarica l'app Stockscreener
840.84
3.78%
30.60
Dopo l'orario di chiusura:
840.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$810.24
Aprire:
$817.17
Volume 24 ore:
744.71K
Relative Volume:
0.77
Capitalizzazione di mercato:
$86.57B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
20.49
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+5.37%
1M Prestazione:
+24.26%
6M Prestazione:
+7.47%
1 anno Prestazione:
+47.06%
Intervallo 1D:
$815.38
$844.92
Intervallo di 1 settimana:
$792.57
$844.92
Portata 52W:
$541.00
$844.92
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Ninth Circuit Revives Regeneron Kickback Whistleblower Lawsuit - Bloomberg Law News
Pasatru’s FDA Approval Puts Regeneron’s Rare-Disease Playbook To The Test - insights.citeline.com
Regeneron Announces Investor Conference Presentations - marketscreener.com
Why Does Regeneron Pharmaceuticals (NASDAQ:REGN) Merit A Fresh Look? - Kalkine Media
REGN Looks 4.9% Undervalued on GF Value™ After FDA Approval - GuruFocus
US FDA approves Regeneron's rare bone disorder drug - Reuters
Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition - marketscreener.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP - Investing.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With Fibrodysplasia Ossificans Progressiva - quiverquant.com
Regeneron rare bone disorder therapy approved (REGN:NASDAQ) - Seeking Alpha
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact Levi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week HighWhat's Next? - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD - Investing.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Oxbow Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
M. Kulyk & Associates LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meeder Asset Management Inc. Invests $4.46 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Pallas Capital Advisors LLC Takes $1.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Danske Bank A S Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Global Retirement Partners LLC Makes New $975,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock holds near a 52-week high after a strong quarter. - Ad-hoc-news.de
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Promising Biotech Stocks To Watch TodayAugust 18th - MarketBeat
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact The Gross Law Firm - PR Newswire
Regeneron ends eye disease study due to antibody’s safety profile - BioSpace
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - TMX Newsfile
Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile - BioSpace
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Resilient Regeneron stock trades close to 52-week high as dividend and earnings support valuation - AD HOC NEWS
UNIVEST FINANCIAL Corp Takes $8.15 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action LawsuitHagens Berman Sobol Shapiro LLP - PR Newswire
Perigon Wealth Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Invests $160.53 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron halts early-stage uveitis trial after safety event - The Pharma Letter
4,376 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Citizens Financial Group Inc. RI - MarketBeat
Deutsche Bank AG Makes New $323.25 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Grandfield & Dodd LLC Purchases Shares of 36,628 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
BlackRock Inc. Makes New $5.68 Billion Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
4,778 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by B & T Capital Management DBA Alpha Capital Management - MarketBeat
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Samsung Biologics? No — Samchundang Pharm Reaches Landmark Settlement in Eylea Biosimilar Patent Dispute, Clearing Path for Global Commercialization - finance.biggo.com
Regeneron Pharmaceuticals, Inc. Notice of September 14, - GlobeNewswire
Resilient Regeneron stock hovers near 52-week high after dividend and analyst target hike - AD HOC NEWS
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron - GlobeNewswire
Biotech Stocks To ResearchAugust 17th - MarketBeat
Can Regeneron Pharmaceuticals (NASDAQ:REGN) Extend Its Run? - Kalkine Media
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
REGN Maintained by Leerink Partners -- Price Target Raised to $8 - GuruFocus
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
176.97%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):